Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease.

Ma QL, Teng E, Zuo X, Jones M, Teter B, Zhao EY, Zhu C, Bilousova T, Gylys KH, Apostolova LG, LaDu MJ, Hossain MA, Frautschy SA, Cole GM.

Neurobiol Dis. 2018 Jun;114:120-128. doi: 10.1016/j.nbd.2018.02.014. Epub 2018 Mar 6.

PMID:
29501530
2.

Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease.

Sundaram JR, Poore CP, Sulaimee NHB, Pareek T, Cheong WF, Wenk MR, Pant HC, Frautschy SA, Low CM, Kesavapany S.

J Alzheimers Dis. 2017;60(4):1429-1442. doi: 10.3233/JAD-170093.

PMID:
29036814
3.

Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain.

Teter B, LaDu MJ, Sullivan PM, Frautschy SA, Cole GM.

Neuroreport. 2016 Aug 3;27(11):791-5. doi: 10.1097/WNR.0000000000000608.

4.

Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.

Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, Yang F, Chen PP, Glabe CG, Takacs A, Hoffman DR, Frautschy SA, Cole GM.

Neurobiol Dis. 2015 Oct;82:552-560. doi: 10.1016/j.nbd.2015.09.002. Epub 2015 Sep 12.

5.

Clinical development of curcumin in neurodegenerative disease.

Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM, Frautschy SA.

Expert Rev Neurother. 2015 Jun;15(6):629-37. doi: 10.1586/14737175.2015.1044981. Review.

PMID:
26035622
6.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

7.

Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease.

Bilousova T, Taylor K, Emirzian A, Gylys R, Frautschy SA, Cole GM, Teng E.

Neurobiol Dis. 2015 Feb;74:32-40. doi: 10.1016/j.nbd.2014.11.006. Epub 2014 Nov 13.

8.

Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Kiosea NC, Nazari S, Chen PP, Nothias F, Chan P, Teng E, Frautschy SA, Cole GM.

J Neurosci. 2014 May 21;34(21):7124-36. doi: 10.1523/JNEUROSCI.3439-13.2014.

9.

Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA.

J Biol Chem. 2013 Feb 8;288(6):4056-65. doi: 10.1074/jbc.M112.393751. Epub 2012 Dec 21.

10.

Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers.

Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, Hayes J, Jones MR, Lichti-Kaiser K, Yang F, Gale GD, Tseng CH, Tan M, Xie CW, Straudinger JL, Klärner FG, Schrader T, Frautschy SA, Grassi C, Bitan G.

Brain. 2012 Dec;135(Pt 12):3735-48. doi: 10.1093/brain/aws289. Epub 2012 Nov 26.

11.

PAK in Alzheimer disease, Huntington disease and X-linked mental retardation.

Ma QL, Yang F, Frautschy SA, Cole GM.

Cell Logist. 2012 Apr 1;2(2):117-125.

12.

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM.

Alzheimers Res Ther. 2012 Oct 29;4(5):43. doi: 10.1186/alzrt146. eCollection 2012.

13.

Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.

Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF.

Mol Neurodegener. 2012 Apr 4;7:12. doi: 10.1186/1750-1326-7-12.

14.

Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1.

Borbon IA, Hillman Z, Duran E Jr, Kiela PR, Frautschy SA, Erickson RP.

Pharmacol Biochem Behav. 2012 Mar;101(1):125-31. doi: 10.1016/j.pbb.2011.12.009. Epub 2011 Dec 17.

15.

[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR.

Neurobiol Dis. 2011 Sep;43(3):565-75. doi: 10.1016/j.nbd.2011.05.003. Epub 2011 May 13.

16.

What was lost in translation in the DHA trial is whom you should intend to treat.

Frautschy SA, Cole GM.

Alzheimers Res Ther. 2011 Jan 20;3(1):2. doi: 10.1186/alzrt61.

17.

Dietary fatty acids and the aging brain.

Cole GM, Ma QL, Frautschy SA.

Nutr Rev. 2010 Dec;68 Suppl 2:S102-11. doi: 10.1111/j.1753-4887.2010.00345.x. Review.

18.

Why pleiotropic interventions are needed for Alzheimer's disease.

Frautschy SA, Cole GM.

Mol Neurobiol. 2010 Jun;41(2-3):392-409. doi: 10.1007/s12035-010-8137-1. Epub 2010 May 2. Review.

19.

Thinking outside the box about COX-1 in Alzheimer's disease.

Frautschy SA.

Neurobiol Dis. 2010 Jun;38(3):492-4. doi: 10.1016/j.nbd.2010.02.009. Epub 2010 Mar 2.

20.

Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Cole GM, Frautschy SA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8. Review.

Supplemental Content

Loading ...
Support Center